NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it intends to sell its HemoCue point-of-care diagnostics business and will report results associated with that business, as well as the OralDNA business that it sold last month, as discontinued operations in its fourth-quarter financials. Quest said that it expects to take a charge of $89.5 million, or $.56 per share, related to the discontinued operations for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.